Uspehi Molekularnoj Onkologii

根据国际医学期刊编辑委员会（ICMJE）的建议，只有对研究的构思与设计或数据的分析与解释作出重大贡献、积极参与论文撰写或作出关键修改、参与最终定稿批准并愿意对文章内容负责的人，才有资格署名为作者。 模型中文摘要

According to the recommendations of the ICMJE, the right to be referred as the author have those persons who made significant contribution to the conception and design of the study or in the data analysis and its interpretation, actively participated in drafting the article or making fundamental changes, participated in the final approval of the version that is to be published and ready to take re…

文章末尾必须说明所有作者的利益冲突；利益冲突指任何可能影响结果、数据解释及其客观认知的关系或个人利益，包括与任何组织的财务关系与合作（如收取报酬、教育资助、参加专家委员会、会员身份、工作关系、咨询工作、持有私人财产中的店铺等）或非财务利益（如个人或职业关系、熟识等）。 模型中文摘要

At the end of the article you must specify conflicts of interest for all authors. Conflict of interest implies the existence of any relations and/or personal interest that potentially can affect results, interpretation of data, its objective perception, such as financial relations and cooperation with any organizations (e.g., receipt of fees, educational grants, participation in expert councils, m…

作者保留版权，并授予期刊首次发表权，作品同时以知识共享署名许可（Creative Commons Attribution License）授权，允许他人在注明作者身份和首次发表于本期刊的情况下分享作品；作者还可另行签订非排他性分发合同安排（如存入机构知识库或出版成书），但需注明作品首次发表于本期刊。 模型中文摘要

Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, addition…

《分子肿瘤学进展》对所有投稿的科学稿件强制实行双盲同行评审，即审稿人不知道稿件作者身份，作者也不与审稿人保持任何联系；同行评审由编委会成员及受邀担任独立审阅人的俄罗斯和国际生命科学领域权威专家进行，由主编、副主编或科学编辑选择审阅人。 模型中文摘要

A double-blind peer review method is mandatory for processing of all scientific manuscripts submitted to the editorial stuff of "Advances in molecular oncology". This implies that neither the reviewer is aware of the authorship of the manuscript, nor the author maintains any contact with the reviewer. Members of the editorial board and leading Russian and international experts in corresponding are…

禁止发表含有文字、观点、数据剽窃的作品，作者应提交完全原创的作品；他人成果应恰当引用或引述，已发表文字的引用须以直接引语形式书写并注明原始出处；编辑部使用查重软件Antiplagiat和Google Scholar对投稿进行筛查，如发现非法借用的文字和图形元素或文本原创度低，将作相应处理。 模型中文摘要

Publication of works containing plagiarism of text, ideas, data is prohibited. Authors should submit fully original works. Results of other authors’ work should be appropriately cited or quoted; quotations of a text previously published should be written as the direct speech with the obligatory indication of the original source. The editorial board of the journal checks the material using plagiari…

在《分子肿瘤学进展》接受和发表之前，作者可以将投稿作为预印本发布在个人或公共网站上；作为投稿流程的一部分，作者须确认稿件未曾发表且未同时投往他处；文章在本刊发表后，建议作者在个人或公共网站分享时使用期刊网站上该文章的链接。 模型中文摘要

Prior to acceptance and publication in "Advances in molecular oncology" authors may make their submissions available as preprints on personal or public websites. As part of submission process, authors are required to confirm that the submission has not been previously published, nor has been submitted. After a manuscript has been published in "Advances in molecular oncology" we suggest that the li…

允许并鼓励作者在投稿之前和投稿期间将其作品在线发布（如存入机构知识库或发布在个人网站上），因为这可以促进富有成效的交流，并带来更早和更多的引用。 模型中文摘要

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).